BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Letrozole: trial readouts and FDA decisions
5 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 1 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Pfizer, Jiangsu HengRui Medicine Co., Ltd., Tolmar Inc., Olema Oncology, Inc., Jiangsu HengRui Medicine Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Olema Oncology, Inc.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P1/P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06974929 A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer | Breast Cancer | recruiting | 80 |
| 2026-12-30 est. | P3 | Pfizer PFE | NCT05909397 Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer | Breast Cancer | active not recruiting | 59 |
| 2026-12-31 est. | P2 | Pfizer PFE | NCT04553133 PF-07104091 as a Single Agent and in Combination Therapy | Small Cell Lung Cancer; Ovarian Cancer; Breast Cancer | active not recruiting | 157 |
| 2027-01-30 est. | P3 | Tolmar Inc. | NCT04906395 Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer | Breast Cancer | active not recruiting | 250 |
| 2026-12 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05780567 Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Canc | Breast Cancer | active not recruiting | 1946 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-31 est. | P3 | Olema Oncology, Inc. OLMA | NCT06016738 OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer; HER2 Neg | active not recruiting | 510 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.